New Oral Pill Shows Promise for Weight Loss and Blood Sugar Management

A recent trial has shown that a new daily pill, orforglipron, is more effective in aiding weight loss and managing blood sugar than currently available medications. This breakthrough could significantly impact the growing market for oral weight-loss drugs.

The introduction of the injectable weight-loss medication semaglutide, often recognized by brand names like Wegovy and Ozempic, marked a notable change in the weight-loss medication landscape a few years back.

Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) medications. Essentially, these drugs mimic a gut hormone released shortly after eating, signaling to the brain that the body is full, which in turn slows digestion and promotes insulin release. GLP-1 drugs have been proven to be quite effective for managing type 2 diabetes and facilitating weight loss.

Despite its effectiveness, one hurdle with semaglutide is the necessity for injections—into the stomach, thighs, or arms. This can be a challenge for individuals averse to needles or hesitant about self-injection due to the inconvenience it presents.

Additionally, injectable GLP-1 drugs require refrigeration throughout the supply chain, which can be particularly problematic in low- and middle-income countries.

Given these concerns, researchers have been looking into oral formulations of semaglutide.

Current findings indicate that oral semaglutide is effective but comes with stipulations: it has to be taken on an empty stomach, and users need to wait 30 minutes before consuming anything. Moreover, it is costly to produce and displays lower bioavailability compared to its injectable counterpart, meaning only about 1% of the drug ingested is absorbed enough to have an effect.

Recently, a phase 3 clinical trial revealed that orforglipron, a new oral weight-loss medication, may have addressed these challenges, showing greater efficacy than existing oral semaglutide options.

Details of the Trial

This latest 52-week trial included 1,698 adults with type 2 diabetes across six countries, aiming to compare orforglipron with current oral semaglutide treatments.

The researchers primarily focused on reducing HbA1c levels, a standard measure of blood sugar control, where a level of 6.5% or higher indicates diabetes. Starting from an average baseline HbA1c of 8.3%, participants taking orforglipron experienced a reduction between 1.71% and 1.91% after one year, whereas those on semaglutide only saw a 1.47% decrease.

Not only did orforglipron meet the trial’s benchmarks, but it also surpassed semaglutide concerning blood sugar control. Additionally, participants taking orforglipron lost more weight—averaging between 6.1kg and 8.2kg—compared to a 5.3kg loss for those on semaglutide.

However, the trial did highlight issues with tolerability. GLP-1 medications are known to cause gastrointestinal side effects like nausea and diarrhea. In this trial, 59% of orforglipron users reported such issues, compared to 37-45% for semaglutide.

This variance in side effects may be due to different peak drug concentrations in orforglipron, causing approximately 10% of participants to stop treatment because of adverse effects, as opposed to 4-5% for semaglutide.

Implications for the Market

The findings position orforglipron, developed by Eli Lilly, as a strong competitor to semaglutide in the market.

Interestingly, orforglipron belongs to a new category called small-molecule drugs. These synthetic compounds are small enough to be absorbed through the gut wall to engage GLP-1 receptors, even though their structure isn’t similar to that of a GLP-1 hormone.

On the other hand, oral semaglutide is a peptide drug, featuring an amino acid structure closely resembling natural GLP-1. Because orforglipron is a small-molecule drug, it’s likely cheaper and easier to manufacture than peptide-based options like semaglutide.

Moreover, orforglipron does not require refrigeration, which is a considerable advantage over injectable formulations—a particularly vital factor for improving access in regions with unreliable cold chain infrastructure.

That said, it’s unclear how orforglipron will fare against oral semaglutide once it’s widely available.

While the most recent trial demonstrates orforglipron’s superiority in controlling blood sugar and facilitating weight loss, its higher prevalence of side effects may temper expectations. In what is an already saturated market, long-term adherence may hinge just as much on tolerability as it does on efficacy.

Orforglipron is still being tested in individuals with obesity but not diabetes.